Lilly and AstraZeneca gang up on Merck in Alzheimer's

Eli Lilly is to pay AstraZeneca up to $500m in development and regulatory milestone payments, the first $50m of which could be due in the first half of 2015, under a new deal to jointly develop and commercialize AstraZeneca's AZD3293. The oral beta secretase cleaving enzyme (BACE) inhibitor is currently in early clinical development as a potential treatment for Alzheimer's disease.

Eli Lilly is to pay AstraZeneca up to $500m in development and regulatory milestone payments, the first $50m of which could be due in the first half of 2015, under a new deal to jointly develop and commercialize AstraZeneca's AZD3293. The oral beta secretase cleaving enzyme (BACE) inhibitor is currently in early clinical development as a potential treatment for Alzheimer's disease.

AZD3293 was discovered at Astex Pharmaceuticals which was acquired by Japanese firm Otsuka Pharmaceutical last year for around $886m (

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Neurological

Evidence Growing For GLP-1s To Treat Alzheimer’s And Parkinson’s

 

GLP-1 receptor agonists could play a big role in tackling neurodegeneration and a new academic study has raised expectations of Novo Nordisk’s latest semaglutide Phase III results

As More DLL3 Bispecifics Advance, Doctors Are Adjusting To CRS, ICANS

 
• By 

Amgen’s Imdelltra for small-cell lung cancer is one of two bispecific T-cell engagers approved for solid tumors, but data at the WCLC meeting show other DLL3-targeting BiTEs may be on the way.

Novo Nordisk’s Semaglutide Shows Promise In Hidradenitis Suppurativa

 

An academic study of GLP-1 agonist showed promise in patients with the painful skin condition but with no signs that the Danish drugmaker will pursue the indication, smaller players in the space may be interested.

Biogen Joins Molecular Glue Degrader Club with Neomorph Pact--Test-1

 
• By 

As it posts third-quarter numbers that again reveal the decline of revenues from its multiple sclerosis portfolio, the US biotech major is entering into the hot area of targeted protein degradation to boost its immunology and neurology pipeline.

More from Therapeutic Category

Scrip Data Article Without An Author

"Neque porro quisquam est qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit..."

Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]

Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.

Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.